you obviously haven't been following my posts because if you have, you'd know that the one IND (HemaXellerate) got abandoned when Konman Koos couldn't get funding for the P1 trial and the other NDA (DcellVax) never got NDA approval because the company is so inept in its application process that it failed to answer very basic questions that the FDA needed to know. The FDA kicked back the NDA for DcellVax a few times. Then Regen abandoned that too. Dr. Kesari wasn't all that good in helping Regen answer the FDA's questions. That's an undeniable fact.
It also doesn't help that Reject Bio is on the OTC. But that's on purpose because deadbeat dave would have more scrutiny on his shady accounting and preferred offering tricks if he was on NASDAQ.
News 
Market Data 
Discover 
